Progress in Measurement Instruments for Acute and Chronic Gout Studies
- 8 October 2009
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 36 (10) , 2346-2355
- https://doi.org/10.3899/jrheum.090371
Abstract
Consensus exercises have identified and prioritized domains of measurement for studies in acute and chronic gout. In parallel, the technical properties of instruments for measurement in many of these domains have been assessed, with the main objective to consider the instruments in the context of the OMERACT filter of truth, discrimination, and feasibility. These data were presented and discussed at OMERACT 9 in the gout workshop, in breakout groups, and at informal meetings of the gout group. In acute gout, instruments for domains of pain, joint swelling, joint tenderness, and patient and physician global assessment have been assessed. In chronic gout, some validation exercises have been performed in instruments for domains serum urate, tophus measurement, health-related quality of life (HRQOL). In voting at OMERACT 9, the Medical Outcomes Study Short-Form 36 was endorsed as a valid instrument for measurement of HRQOL. Methods of tophus measurement were considered to have met some criteria of the OMERACT filter, but these require further work, particularly regarding sensitivity to change over shorter time periods. Priorities for future research include measurement of joint inflammation in acute gout and disability in acute and chronic gout.Keywords
This publication has 29 references indexed in Scilit:
- Outcome Domains for Studies of Acute and Chronic GoutThe Journal of Rheumatology, 2009
- A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic goutAnnals of the Rheumatic Diseases, 2008
- Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trialThe Lancet, 2008
- Assessment of outcome in clinical trials of gout a review of current measuresRheumatology, 2007
- Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute goutCurrent Medical Research and Opinion, 2007
- Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of goutRheumatology, 2007
- Comparison of Oral Prednisolone/Paracetamol and Oral Indomethacin/Paracetamol Combination Therapy in the Treatment of Acute Goutlike Arthritis: A Double-Blind, Randomized, Controlled TrialAnnals of Emergency Medicine, 2007
- Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trialArthritis & Rheumatism, 2004
- Response relationship of VAS and Likert scales in osteoarthritis efficacy measurementOsteoarthritis and Cartilage, 2003
- Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritisBMJ, 2002